Angion Biomedica Corp. announced the appointment of several members to its management team, including Mr. Kevin Norrett as senior vice president and chief commercial officer, Dr. Tracy Mayne as vice president of medical affairs, Mr. Daniel Iazzetti as vice president of human resources and Mr. David Upchurch as vice president of technical operations. Mr. Norrett brings over 20 years of experience to Angion. Over the course of his career, he has become an expert at helping clinical-stage companies transition to full commercialization. Most recently, he served as vice president of marketing, market access and commercial operations at Aimmune Therapeutics, where he helped build the commercial function and the launch strategy. Prior to this, Mr. Norrett was vice president of market access and commercial development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching its first therapeutic into nephrology and cardiology. Dr. Mayne joins the Angion team with decades of pharmaceutical and clinical experience. He most recently served as head of health policy and systems research at Genentech. Mr. Iazzetti bring more than 20 years of human resources and talent acquisition experience to Angion. He is an expert in helping companies align talent with business strategies and passionate about leveraging technology to help companies scale. Mr. Iazzetti formerly served as the head of human resources for Five Prime Therapeutics a, clinical stage immune-oncology company. Mr. Upchurch has played numerous roles in the pharmaceutical development and lifecycle phases over 25 years, including preparing national and international registrations, engineering and assembling global outsourced supply chains and improving compliance status at multiple manufacturing sites.